ClinicalTrials.gg
Not yet recruitingNCT07424534Updated Mar 5, 2026

Predictive Models on Psychosocial Profile, Fatigue and Sleep Quality

An observational study in Fibromyalgia, sponsored by University of Castilla-La Mancha. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by University of Castilla-La Mancha · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 151 studies in Fibromyalgia with a site in Spain — 16 open to participants now, 21 under way, none of them phase 3. Fibromyalgia · Spain.

Planned enrollment
3rd of 15
150 · median 90
Started
2026
with 5 others
Observational
15 of 151
2 open now
Primary completion
2026-11
later than 15 of 20 live
Registered
143rd of 151
by date
Lead sponsor
6 of 151
University of Castilla-La Mancha

Among the 151 studies in Fibromyalgia with a site in Spain, this one is the 3rd largest by planned enrollment of the 15 observational ones that give a count, is one of 6 that started in 2026, is one of 15 observational ones, reaches primary completion later than 15 of the 20 other live ones, and was the 143rd registered.

Fibromyalgia

1,245 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

16 of the 151 studies in Fibromyalgia with a site in Spain are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 51 (32%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies in Fibromyalgia with a site in Spain, or all of them as a file.
02

Study summary

The primary goal of this research project is to develop different prediction models in fibromyalgia disease through the application of machine learning techniques and to assess the explainability of the results. As specific objective the research project intends to evaluate the influence of psychosocial variables, fatigue, and sleep quality on the prediction of disease severity in patients with fibromyalgia using an artificial intelligence-based model.

Read the detailed description

Fibromyalgia (FM) is a condition characterized by chronic musculoskeletal pain, the pathophysiology of which remains unclear. In addition, this disorder is frequently associated with sleep disturbances, pronounced fatigue, morning stiffness, poor quality of life, cognitive alterations (primarily memory-related problems), and psychological disturbances, including depression, anxiety, and stress.

FM is significantly more prevalent in women, with an estimated female-to-male ratio of approximately 3:1. Its prevalence in the adult population is estimated at 2-3%, increasing with age and peaking between 45 and 65 years. The socioeconomic and healthcare burden of this condition is substantial, as FM is associated with high rates of medical consultations, unemployment, work disability, and the need for disability-related financial support.

FM has been linked to higher levels of negative affect, defined as a general state of distress encompassing aversive emotions such as sadness, fear, anger, and guilt. Patients with FM commonly exhibit elevated levels of anxiety, depression, pain catastrophizing, and stress, which are associated with worsening of symptoms, including cognitive impairments.

In recent years, machine learning, data mining, and artificial intelligence (AI) techniques have been successfully applied to the development of computer-aided diagnosis (CAD) systems for the identification of complex health conditions, achieving good levels of accuracy and efficiency by recognizing potentially meaningful patterns in health-related data. Accordingly, these technologies provide powerful tools for multivariable data analysis, enabling model-based predictions and offering a clear advantage in risk assessment across a wide range of diseases. In addition, these approaches not only support the development of clinical predictive models but also enhance clinicians' ability to interpret and apply their results in practice.

Explainable machine learning models allow clinical experts to make data-driven decisions and to deliver personalized treatments while maintaining a high standard of care. These models fall within the field of explainable artificial intelligence (XAI), which aims to develop interpretable models that preserve high predictive accuracy while improving the transparency, understanding, and trustworthiness of model outputs.

A previous publication by our research group demonstrated, using machine learning models, a strong association between mental health factors-particularly anxiety and depression-and fibromyalgia severity, with a greater influence than pain intensity itself. Other prevalent symptoms of fibromyalgia, such as fatigue and sleep quality disturbances, are also considered by patients to be major contributors to reduced quality of life, often perceived as more impactful than pain.

Accordingly, the present study aims to develop predictive models of fibromyalgia severity using machine learning and explainable artificial intelligence techniques, incorporating fatigue and sleep quality as novel variables in the analysis.

Understanding the individual and combined relevance of these psychosocial components in determining patients' clinical status may contribute to improved disease management and more personalized treatment strategies, ultimately enhancing the quality of care.

03

Conditions studied

  • Fibromyalgia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of adult volunteers diagnosed with fibromyalgia who meet the eligibility criteria and provide written informed consent to participate in the study. Participants will be recruited from a primary care center within the Spanish public healthcare system.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 65 years.
  • Fullfilled the 2010 American Collegue of Rheumathology criteria for fibromyalgia.
  • Understanding of spoken and written Spanish.

Exclusion criteria

Exclusion Criteria:

  • Diagnosed psychiatric pathology.
  • Rheumatic pathology not medically controlled.
  • Neurological pathologies that make evaluations difficult.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Disease severity

    For this purpose, the Spanish validated version of the Fibromyalgia Impact Questionnaire (FIQ) will be used. The questionnaire comprises several components assessing physical, psychological, and social status, as well as overall well-being. It consists of 10 items scored on 0-10 scales, yielding a total score ranging from 0 to 100, with higher scores indicating greater disease impact and poorer quality of life.

    Time frame: Baseline

Secondary outcomes

  1. Sleep quality

    Sleep quality will be assessed using the Spanish validated version of the Medical Outcomes Study Sleep Scale (MOS-SS). This instrument consists of 12 items evaluating six sleep domains: sleep disturbance (ability to initiate and maintain sleep), sleep adequacy (sufficiency of sleep to feel rested), sleep quantity (number of hours of sleep), somnolence (daytime sleepiness), snoring, and shortness of breath or headache. A sleep problems index can be derived on a 0-100 scale, with higher scores indicating greater sleep-related problems.

    Time frame: Baseline

  2. Fatigue

    Fatigue severity will be assessed using the Spanish adaptation of the Multidimensional Fatigue Inventory (MFI). This is a self-administered questionnaire consisting of 20 items. It comprises five subscales that analytically assess general fatigue, physical fatigue, reduced activity, reduced motivation, and mental fatigue. The total score ranges from 0 to 100, with higher scores indicating greater fatigue severity.

    Time frame: Baseline

  3. Pain intensity

    It will be measured with a visual analog scale (VAS) of 100 millimeters in length. The subject has to indicate the level of pain he feels, being 0 the absence of pain and 100 the maximum imaginable.

    Time frame: Baseline

  4. Depression

    Depressive symptoms will be assessed using the Spanish adaptation of the Beck Depression Inventory-II (BDI-II). This instrument consists of 21 items designed to measure affective and cognitive status, as well as the signs and symptoms of depression experienced over the preceding two weeks. Total scores range from 0 to 63, where higher scores indicate greater severity.

    Time frame: Baseline

  5. Pain catastrophizing

    The Spanish validated version of the Pain Catastrophizing Scale (PCS) will be administered. The PCS consists of 13 items assessing catastrophic cognitive-emotional processes related to pain and encompasses the three main dimensions of catastrophizing: rumination (persistent concern and inability to inhibit pain-related thoughts), magnification (exaggeration of the unpleasantness of pain and expectations of negative consequences), and helplessness (perceived inability to cope with painful situations). Items are rated on a 5-point Likert scale ranging from 0 (never) to 4 (always). The total score is calculated by summing the responses to all 13 items, with higher scores indicating greater levels of pain catastrophizing.

    Time frame: Baseline

  6. Anxiety

    Anxiety will be assessed using the Spanish validated version of the State Anxiety Scale (STAI-S) of the State-Trait Anxiety Inventory (STAI). It consists of 20 items scored on a Likert-type scale from 0 to 3. The score ranges from 0 to 60 points, with higher scores indicating worse anxiety levels.

    Time frame: Baseline

07

Study locations

1 site
  • Rafael Velasco Velasco
    Seville, Seville 41008, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Nov 2026, 9 months later.

Of 81 non-industry observational studies under Fibromyalgia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 109. This study's planned 9 months is below that.

Counting every sponsor, half of 88 studies reached it within 27 months; a quarter within 8 and three quarters within 91.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2026
First posted
Feb 20, 2026
StartEst.
Feb 24, 2026
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07424534
Collaborators
Tampere University, Andaluz Health Service
Responsible party
Sponsor
First posted
Feb 20, 2026
Start date
Feb 24, 2026 (estimated)
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Mar 5, 2026

Study contacts

Rafael Velasco Velasco, Mr.
Contact
Rafael.Velasco@uclm.es
+34954786735
Rubén Arroyo Fernández, Dr.
Contact
Ruben.Arroyo@uclm.es
+34925803600 ext. 86589
Rafael Velasco Velasco, Mr.
principal investigator · University of Castilla-La Mancha

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion